EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer

Ryan M Reyes, Emily Rios, Shane Barney, Cory M Hugen, Joel E Michalek, Yair Lotan, Edward M Messing, Robert S Svatek

Bladder Cancer · 31.08.2021 · 7 (3) · 285-295

DOI: 10.3233/blc-201535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 03.06.2021. Verfasst von Ryan M Reyes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NCATS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Surveillance regimens for non-muscle invasive bladder cancer (NMIBC) are disparate and controlled trials could inform guidelines. The feasibility of randomizing patients to variable frequency surveillance is unknown. OBJECTIVES: To determine patient willingness to randomization to high frequency (HF) versus low frequency (LF) surveillance regimen for NMIBC and compare patient comfort and healthcare costs across regimens. METHODS: A non-blinded, two-arm, randomized-controlled study of patients with low or low-intermediate risk NMIBC was conducted at two institutions where patients were offered randomization to HF vs. LF surveillance following initial tumor resection. The HF group underwent cystoscopy every three months for 2 years, then every 6 months for 2 years, then annually. The LF group underwent cystoscopy at 9 months following the 3-month cystoscopy, then annually. Assuming 75% of patients approached would agree to enrollment, a sample size of n = 35 patients per arm provided a one-sided 95% exact Clopper-Pearson confidence lower-limit of 60%. RESULTS: Of 70 patients approached, 45 (64.3%) agreed to participate and 25 (35.7%) declined enrollment due to preference for HF. Twelve biopsies were performed, including 4 (19%) of 21 patients in the HF group and 8 (33.3%) of 24 patients in the LF group. Disease recurrence (low grade Ta) was observed in 3 (14.3%) and 5 (20.8%) patients in the HF and LF groups, respectively. No patients experienced high grade recurrence or progression. Both groups had similar patient-reported procedure-related discomfort and quality of life measures over time. Patient out-of-pocket cost and healthcare systems costs were $383.80 more per patient annually in the HF group. CONCLUSIONS: Randomization to variable frequency surveillance is challenging as over a third of patients declined participation. However, these data provide important preliminary insights into the potential effects of surveillance frequency on oncologic and economic outcomes in patients with low and low-intermediate risk bladder cancer.

Schlagwörter

Stichwörter der Autor:innen

Bladder cancerquality of liferecurrencesurveillance

Autor:innen und Institutionen

  • Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Department of Urology, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Department of Epidemiology and Biostatistics, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Urology, University of Rochester, Rochester, NY, USA.

Förderung

  • NIA NIH HHS
  • NCATS NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Reyes, R. M., Rios, E., Barney, S., Hugen, C. M., Michalek, J. E., Lotan, Y., Messing, E. M., & Svatek, R. S. (2021). A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 7(3), 285-295. https://doi.org/10.3233/blc-201535

Vancouver

Reyes RM, Rios E, Barney S, Hugen CM, Michalek JE, Lotan Y, et al. A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2021;7(3):285-295. doi:10.3233/blc-201535

BibTeX
@article{Reyes2021,
  author = {Reyes, Ryan M and Rios, Emily and Barney, Shane and Hugen, Cory M and Michalek, Joel E and Lotan, Yair and Messing, Edward M and Svatek, Robert S},
  title = {A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer},
  journal = {Bladder Cancer},
  year = {2021},
  volume = {7},
  number = {3},
  pages = {285--295},
  doi = {10.3233/blc-201535}
}
Kostenlos starten →